IL101387A - Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets - Google Patents

Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets

Info

Publication number: IL101387A
Authority: IL; Israel
Prior art keywords: droplets; size; composition according; cream; cosmetic
Prior art date: 1992-03-26

Application number

IL10138792A

Other languages

English (en)

Other versions

IL101387A0 (en

Inventor

Aviv Haim

Original Assignee

Pharmos Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-26

Filing date

1992-03-26

Publication date

1999-11-30

1992-03-26 Application filed by Pharmos Ltd filed Critical Pharmos Ltd

1992-03-26 Priority to IL10138792A priority Critical patent/IL101387A/en

1992-11-15 Publication of IL101387A0 publication Critical patent/IL101387A0/xx

1993-03-23 Priority to US08/036,116 priority patent/US6004566A/en

1993-03-25 Priority to DK93908578T priority patent/DK0671903T3/da

1993-03-25 Priority to JP51683693A priority patent/JP4173533B2/ja

1993-03-25 Priority to DE69331335T priority patent/DE69331335T2/de

1993-03-25 Priority to CA002132736A priority patent/CA2132736C/en

1993-03-25 Priority to CA002590810A priority patent/CA2590810A1/en

1993-03-25 Priority to EP93908578A priority patent/EP0671903B1/de

1993-03-25 Priority to ES93908578T priority patent/ES2169042T3/es

1993-03-25 Priority to AU39352/93A priority patent/AU684460B2/en

1993-03-25 Priority to PCT/US1993/002800 priority patent/WO1993018752A1/en

1993-03-25 Priority to AT93908578T priority patent/ATE210425T1/de

1993-03-26 Priority to ZA932170A priority patent/ZA932170B/xx

1993-04-09 Priority to TW82102648A priority patent/TW272131B/zh

1999-05-12 Priority to IL12992199A priority patent/IL129921A/en

1999-11-30 Publication of IL101387A publication Critical patent/IL101387A/en

Links

230000000699 topical effect Effects 0.000 title claims description 16
230000009885 systemic effect Effects 0.000 title claims description 8
239000000839 emulsion Substances 0.000 title abstract description 14
239000000203 mixture Substances 0.000 claims abstract description 43
229940079593 drug Drugs 0.000 claims abstract description 34
239000003814 drug Substances 0.000 claims abstract description 34
239000000126 substance Substances 0.000 claims abstract description 19
239000002537 cosmetic Substances 0.000 claims abstract description 14
239000003961 penetration enhancing agent Substances 0.000 claims abstract 2
239000007787 solid Substances 0.000 claims description 13
239000004094 surface-active agent Substances 0.000 claims description 10
239000012736 aqueous medium Substances 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 5
239000006185 dispersion Substances 0.000 claims description 4
239000003623 enhancer Substances 0.000 claims description 4
239000002671 adjuvant Substances 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
239000008271 cosmetic emulsion Substances 0.000 claims description 2
239000008251 pharmaceutical emulsion Substances 0.000 claims description 2
239000003795 chemical substances by application Substances 0.000 claims 2
230000002708 enhancing effect Effects 0.000 claims 2
150000002605 large molecules Chemical class 0.000 claims 1
239000006071 cream Substances 0.000 abstract description 52
238000002360 preparation method Methods 0.000 abstract description 27
238000009472 formulation Methods 0.000 abstract description 20
239000006210 lotion Substances 0.000 abstract description 5
230000000144 pharmacologic effect Effects 0.000 abstract description 4
239000007900 aqueous suspension Substances 0.000 abstract description 2
230000000975 bioactive effect Effects 0.000 abstract description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 33
239000003921 oil Substances 0.000 description 31
235000019198 oils Nutrition 0.000 description 31
229960003529 diazepam Drugs 0.000 description 20
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 20
230000000694 effects Effects 0.000 description 18
229960000905 indomethacin Drugs 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 16
229960004194 lidocaine Drugs 0.000 description 16
241001465754 Metazoa Species 0.000 description 11
229920001525 carrageenan Polymers 0.000 description 11
238000000034 method Methods 0.000 description 11
229920002125 Sokalan® Polymers 0.000 description 10
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 10
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
206010030113 Oedema Diseases 0.000 description 9
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 9
239000000679 carrageenan Substances 0.000 description 8
235000010418 carrageenan Nutrition 0.000 description 8
229940113118 carrageenan Drugs 0.000 description 8
239000003589 local anesthetic agent Substances 0.000 description 8
229960002702 piroxicam Drugs 0.000 description 8
210000003491 skin Anatomy 0.000 description 8
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 8
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 7
229960001259 diclofenac Drugs 0.000 description 7
229960002009 naproxen Drugs 0.000 description 7
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 7
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 7
239000012071 phase Substances 0.000 description 7
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 6
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 6
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 6
241000700198 Cavia Species 0.000 description 6
239000005642 Oleic acid Substances 0.000 description 6
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 6
230000003110 anti-inflammatory effect Effects 0.000 description 6
230000000052 comparative effect Effects 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
239000008387 emulsifying waxe Substances 0.000 description 6
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 6
239000000546 pharmaceutical excipient Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
235000010445 lecithin Nutrition 0.000 description 5
239000000787 lecithin Substances 0.000 description 5
229940067606 lecithin Drugs 0.000 description 5
230000035515 penetration Effects 0.000 description 5
239000013543 active substance Substances 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
239000002270 dispersing agent Substances 0.000 description 4
HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical compound OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
238000002690 local anesthesia Methods 0.000 description 4
229920001993 poloxamer 188 Polymers 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
KWVPFECTOKLOBL-KTKRTIGZSA-N 2-[(z)-octadec-9-enoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCO KWVPFECTOKLOBL-KTKRTIGZSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
206010039897 Sedation Diseases 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
KPHWPUGNDIVLNH-UHFFFAOYSA-M diclofenac sodium Chemical compound [Na+].[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl KPHWPUGNDIVLNH-UHFFFAOYSA-M 0.000 description 3
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
230000036280 sedation Effects 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
230000002936 tranquilizing effect Effects 0.000 description 3
IELOKBJPULMYRW-UHFFFAOYSA-N α-tocopherol succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-UHFFFAOYSA-N 0.000 description 3
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
LWNPNOFGINFGGV-UHFFFAOYSA-N 2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;2-(dimethylamino)ethyl 4-(butylamino)benzoate Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C.CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 LWNPNOFGINFGGV-UHFFFAOYSA-N 0.000 description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
230000003444 anaesthetic effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
238000002296 dynamic light scattering Methods 0.000 description 2
239000000374 eutectic mixture Substances 0.000 description 2
238000001914 filtration Methods 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
229960005015 local anesthetics Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
238000002156 mixing Methods 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
239000008213 purified water Substances 0.000 description 2
230000028527 righting reflex Effects 0.000 description 2
229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
229960002372 tetracaine Drugs 0.000 description 2
GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
210000001364 upper extremity Anatomy 0.000 description 2
239000000341 volatile oil Substances 0.000 description 2
OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
229910002012 Aerosil® Inorganic materials 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
235000003255 Carthamus tinctorius Nutrition 0.000 description 1
244000020518 Carthamus tinctorius Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
241000283715 Damaliscus lunatus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
229940125717 barbiturate Drugs 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
238000009227 behaviour therapy Methods 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
229960002206 bifonazole Drugs 0.000 description 1
238000009835 boiling Methods 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
150000001746 carotenes Chemical class 0.000 description 1
235000005473 carotenes Nutrition 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229940084940 diazepam 5 mg/ml Drugs 0.000 description 1
229960005466 diclofenac diethylammonium Drugs 0.000 description 1
229960001193 diclofenac sodium Drugs 0.000 description 1
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
229960000520 diphenhydramine Drugs 0.000 description 1
HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
229960004192 diphenoxylate Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000000428 dust Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
229960002428 fentanyl Drugs 0.000 description 1
PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
239000008240 homogeneous mixture Substances 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000007794 irritation Effects 0.000 description 1
229960004958 ketotifen Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
229940057917 medium chain triglycerides Drugs 0.000 description 1
229960003632 minoxidil Drugs 0.000 description 1
239000003607 modifier Substances 0.000 description 1
229940052264 other local anesthetics in atc Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
150000002978 peroxides Chemical class 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
150000002990 phenothiazines Chemical class 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
-1 soybean Chemical compound 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000003756 stirring Methods 0.000 description 1
210000000434 stratum corneum Anatomy 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
229960001295 tocopherol Drugs 0.000 description 1
239000011732 tocopherol Substances 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100617 topical lotion Drugs 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960001722 verapamil Drugs 0.000 description 1
235000019155 vitamin A Nutrition 0.000 description 1
239000011719 vitamin A Substances 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940045997 vitamin a Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/062—Oil-in-water emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
- A61K2800/21—Emulsions characterized by droplet sizes below 1 micron
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/926—Topical chemical, e.g. cosmetic or sunscreen

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
Dermatology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Birds (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL10138792A 1992-03-26 1992-03-26 Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets IL101387A (en)

Priority Applications (15)

Application Number	Priority Date	Filing Date	Title
IL10138792A IL101387A (en)	1992-03-26	1992-03-26	Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US08/036,116 US6004566A (en)	1992-03-26	1993-03-23	Topical and transdermal delivery system utilizing submicron oil spheres
AT93908578T ATE210425T1 (de)	1992-03-26	1993-03-25	Topisches und transdermales abgabesystem unter verwendung von submikron-ölkügelchen
CA002590810A CA2590810A1 (en)	1992-03-26	1993-03-25	Topical and transdermal delivery system utilizing submicron oil spheres
AU39352/93A AU684460B2 (en)	1992-03-26	1993-03-25	Topical and transdermal delivery system utilizing submicron oil spheres
DE69331335T DE69331335T2 (de)	1992-03-26	1993-03-25	Topisches und transdermales abgabesystem unter verwendung von submikron-ölkügelchen
CA002132736A CA2132736C (en)	1992-03-26	1993-03-25	Topical and transdermal delivery system utilizing submicron oil spheres
DK93908578T DK0671903T3 (da)	1992-03-26	1993-03-25	Topisk og transdermalt tilførselssystem anvendende submikrone oliesfærer
EP93908578A EP0671903B1 (de)	1992-03-26	1993-03-25	Topisches und transdermales abgabesystem unter verwendung von submikron-ölkügelchen
ES93908578T ES2169042T3 (es)	1992-03-26	1993-03-25	Sistema de suministro topico y transdermico que utiliza esferas de aceite submicronicas.
JP51683693A JP4173533B2 (ja)	1992-03-26	1993-03-25	超微小油球体を用いての局部用及び経皮用投与システム
PCT/US1993/002800 WO1993018752A1 (en)	1992-03-26	1993-03-25	Topical and transdermal delivery system utilizing submicron oil spheres
ZA932170A ZA932170B (en)	1992-03-26	1993-03-26	Topical and transdermal delivery system utilizing submicron oil spheres
TW82102648A TW272131B (de)	1992-03-26	1993-04-09
IL12992199A IL129921A (en)	1992-03-26	1999-05-12	Topical and transdermal delivery compositions utilizing submicron oil droplets and these compositions comprising an active ingredient

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IL10138792A IL101387A (en)	1992-03-26	1992-03-26	Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US08/036,116 US6004566A (en)	1992-03-26	1993-03-23	Topical and transdermal delivery system utilizing submicron oil spheres

Publications (2)

Publication Number	Publication Date
IL101387A0 IL101387A0 (en)	1992-11-15
IL101387A true IL101387A (en)	1999-11-30

Family

ID=26322424

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL10138792A IL101387A (en)	1992-03-26	1992-03-26	Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
IL12992199A IL129921A (en)	1992-03-26	1999-05-12	Topical and transdermal delivery compositions utilizing submicron oil droplets and these compositions comprising an active ingredient

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL12992199A IL129921A (en)	1992-03-26	1999-05-12	Topical and transdermal delivery compositions utilizing submicron oil droplets and these compositions comprising an active ingredient

Country Status (12)

Country	Link
US (1)	US6004566A (de)
EP (1)	EP0671903B1 (de)
JP (1)	JP4173533B2 (de)
AT (1)	ATE210425T1 (de)
AU (1)	AU684460B2 (de)
CA (2)	CA2132736C (de)
DE (1)	DE69331335T2 (de)
DK (1)	DK0671903T3 (de)
ES (1)	ES2169042T3 (de)
IL (2)	IL101387A (de)
WO (1)	WO1993018752A1 (de)
ZA (1)	ZA932170B (de)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ260018A (en) *	1994-03-03	1995-10-26	Bomac Lab Ltd	Benzimidazole compositions and anthelmintic compositions
GB9409778D0 (en)	1994-05-16	1994-07-06	Dumex Ltd As	Compositions
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
AT408067B (de) *	1995-03-17	2001-08-27	Gebro Pharma Gmbh	Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung
EP0760237A1 (de) *	1995-08-30	1997-03-05	Cipla Limited	Öl-in-Wasser-Mikroemulsionen
AU7689996A (en) *	1995-12-12	1997-07-03	Vesifact Ag	Cortisone spray for topical administration
US6572880B2 (en) *	1996-10-24	2003-06-03	Pharmaceutical Applications Associates Llc	Methods and transdermal compositions for pain relief
KR100294084B1 (ko) *	1998-06-02	2001-09-22	성재갑	비-스테로이드성소염진통제의경피흡수투여용조성물및이를포함하는경피흡수투여용제형
EP0858805A3 (de) *	1997-02-13	1998-09-02	National Research Institute of Chinese Medicine	Transdermale Oxicamzubereitungen
TWI241915B (en)	1998-05-11	2005-10-21	Ciba Sc Holding Ag	A method of preparing a pharmaceutical end formulation using a nanodispersion
US6946144B1 (en) *	1998-07-08	2005-09-20	Oryxe	Transdermal delivery system
US7220427B2 (en) *	1998-07-08	2007-05-22	Oryxe	Mixture for transdermal delivery of low and high molecular weight compounds
ES2211151T3 (es)	1998-08-19	2004-07-01	Skyepharma Canada Inc.	Dispersiones acuosas inyectables de propofol.
IT1303692B1 (it) *	1998-11-03	2001-02-23	Chiesi Farma Spa	Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
FR2785803B1 (fr) *	1998-11-17	2005-03-25	Sanofi Sa	Utilisation d'une substance se liant au recepteur peripherique des benzodiazepines dans le traitement des stress cutanes
IL138616A0 (en) *	2000-09-21	2001-10-31	J P M E D Ltd	Oil in glycerin emulsion
US7393548B2 (en) *	1999-03-22	2008-07-01	J.P. M.E.D. Ltd.	Nano oil in glycerin emulsion
EP1169016A1 (de) *	1999-04-14	2002-01-09	The Procter & Gamble Company	Durchsichtige zusammensetzung
IT1312088B1 (it) *	1999-04-21	2002-04-04	Altergon Sa	Cerotto per uso topico contenente eparina e diclofenac.
US6515029B1 (en)	1999-04-23	2003-02-04	Kimberly-Clark Worldwide, Inc.	Absorbent article having a hydrophilic lotionized bodyside liner
DE60012026T2 (de) *	1999-08-26	2004-12-30	Ganeden Biotech, Inc., San Diego	Verwendung von emu-öl als träger für fungizide, antibakterielle und antivirale arzneien
AU7638300A (en) *	1999-10-20	2001-04-30	Vesifact Ag	Microemulsion preconcentrates and microemulsions
US20030104041A1 (en) *	1999-12-16	2003-06-05	Tsung-Min Hsu	Transdermal and topical administration of drugs using basic permeation enhancers
US6565879B1 (en)	1999-12-16	2003-05-20	Dermatrends, Inc.	Topical and transdermal administration of peptidyl drugs with hydroxide-releasing agents as skin permeation enhancers
US6558695B2 (en)	1999-12-16	2003-05-06	Dermatrends, Inc.	Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
US20050037073A1 (en) *	2000-01-13	2005-02-17	Alpharx Inc.	Solid self-emulsifying dosage form for improved delivery of poorly soluble hydrophobic compounds and the process for preparation thereof
FR2805761B1 (fr) *	2000-03-02	2002-08-30	Mainelab	Nanocapsules lipidiques, procede de preparation et utilisation comme medicament
MXPA02009275A (es) *	2000-03-23	2004-09-06	Collaborative Technologies Inc	Metodo para preparar dispersiones de alta presion/alto esfuerzo cortante que contienen ingredientes fisiologicamente activos.
USRE44145E1 (en)	2000-07-07	2013-04-09	A.V. Topchiev Institute Of Petrochemical Synthesis	Preparation of hydrophilic pressure sensitive adhesives having optimized adhesive properties
FR2811564B1 (fr) *	2000-07-13	2002-12-27	Oreal	Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
US6503526B1 (en)	2000-10-20	2003-01-07	Kimberly-Clark Worldwide, Inc.	Absorbent articles enhancing skin barrier function
US6756520B1 (en)	2000-10-20	2004-06-29	Kimberly-Clark Worldwide, Inc.	Hydrophilic compositions for use on absorbent articles to enhance skin barrier
FR2823117A1 (fr) *	2000-11-14	2002-10-11	Pharmascience Lab	Composition pharmaceutique ou cosmetique ainsi que l'utilisation d'au moins un compose actif pour inhiber la migration des cellules de langerhans
US20020165286A1 (en) *	2000-12-08	2002-11-07	Hanne Hedeman	Dermal anti-inflammatory composition
US20020128615A1 (en)	2000-12-22	2002-09-12	Tyrrell David John	Absorbent articles with non-aqueous compositions containing anionic polymers
US7771735B2 (en)	2000-12-22	2010-08-10	Kimberly-Clark Worldwide, Inc.	Absorbent articles with compositions for reducing irritation response
US6749860B2 (en)	2000-12-22	2004-06-15	Kimberly-Clark Worldwide, Inc.	Absorbent articles with non-aqueous compositions containing botanicals
JP4098967B2 (ja) *	2001-04-18	2008-06-11	花王株式会社	ダイラタンシー組成物
US8840918B2 (en)	2001-05-01	2014-09-23	A. V. Topchiev Institute of Petrochemical Synthesis, Russian Academy of Sciences	Hydrogel compositions for tooth whitening
US20050215727A1 (en)	2001-05-01	2005-09-29	Corium	Water-absorbent adhesive compositions and associated methods of manufacture and use
AU2002316053A1 (en)	2001-05-01	2002-11-11	A.V. Topchiev Institute Of Petrochemical Synthesis	Two-phase, water-absorbent bioadhesive composition
US8541021B2 (en)	2001-05-01	2013-09-24	A.V. Topchiev Institute Of Petrochemical Synthesis	Hydrogel compositions demonstrating phase separation on contact with aqueous media
US8206738B2 (en)	2001-05-01	2012-06-26	Corium International, Inc.	Hydrogel compositions with an erodible backing member
US20050113510A1 (en)	2001-05-01	2005-05-26	Feldstein Mikhail M.	Method of preparing polymeric adhesive compositions utilizing the mechanism of interaction between the polymer components
WO2002087645A1 (en)	2001-05-01	2002-11-07	A.V. Topchiev Institute Of Petrochemical Synthesis	Hydrogel compositions
WO2002089849A1 (en) *	2001-05-07	2002-11-14	Corium International	Compositions and delivery systems for administration of a local anesthetic agent
US20040265268A1 (en) *	2001-08-18	2004-12-30	Deepak Jain	Compositions and methods for skin rejuvenation and repair
DE10141650C1 (de)	2001-08-24	2002-11-28	Lohmann Therapie Syst Lts	Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
DE10164531A1 (de) *	2001-12-31	2003-07-17	Pharmatech Gmbh	Zubereitung zur Oberflächenanästhesie der Haut
JP4549625B2 (ja) *	2002-01-05	2010-09-22	株式會社アモーレパシフィック	人参サポニン代謝産物を有効成分とする微細乳化粒子及びその製造方法、並びにこれを含有する皮膚老化防止用の化粧料組成物
DE10200578A1 (de) *	2002-01-09	2003-07-10	Roehm Gmbh	Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6579543B1 (en) *	2002-02-22	2003-06-17	Jackie H. McClung	Composition for topical application to skin
IL157535A0 (en) *	2003-08-21	2004-03-28	Topimed Ltd	Preparations for the prevention of skin atrophy
US20050059583A1 (en)	2003-09-15	2005-03-17	Allergan, Inc.	Methods of providing therapeutic effects using cyclosporin components
AU2004274000B2 (en) *	2003-09-19	2009-07-30	Drugtech Corporation	Pharmaceutical delivery system
US20060140990A1 (en) *	2003-09-19	2006-06-29	Drugtech Corporation	Composition for topical treatment of mixed vaginal infections
WO2005074894A1 (en)	2004-01-30	2005-08-18	Corium International	Rapidly dissolving film for delivery of an active agent
MX2007001512A (es)	2004-08-05	2007-04-20	Corium Int Inc	Composicion adhesiva.
KR100623013B1 (ko) *	2004-09-04	2006-09-19	김영대	나노에멀션, 그의 용도 및 제조방법
US20060079558A1 (en) *	2004-09-27	2006-04-13	Bridge Pharma. Inc.	R-isomer of 2-{2[N-(2-indanyl)-N-phenylamino]ethyl}piperidine and other dermal anesthetics
WO2006036936A2 (en) *	2004-09-27	2006-04-06	Bridge Pharma, Inc.	The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
DE102004059613A1 (de) *	2004-12-10	2006-06-14	Liedtke, Rainer K., Dr.	Zusammensetzung und Methode einer topischen Therapie von Neurodermitis
US20060222687A1 (en) *	2005-04-01	2006-10-05	Carter Stephen G	Topical anesthetic
CA2605341A1 (en) *	2005-05-09	2006-11-16	Drugtech Corporation	Modified-release pharmaceutical compositions
US20070015691A1 (en)	2005-07-13	2007-01-18	Allergan, Inc.	Cyclosporin compositions
US9486408B2 (en)	2005-12-01	2016-11-08	University Of Massachusetts Lowell	Botulinum nanoemulsions
WO2007079391A2 (en) *	2006-01-05	2007-07-12	Drugtech Corporation	Drug delivery system for bioadhesion to a vulvovaginal surface
CN101374501A (zh) *	2006-01-05	2009-02-25	药物技术公司	组合物及其使用方法
US20100247653A1 (en) *	2006-04-11	2010-09-30	Hans Lautenschlager	Nanoparticles containing nicotine and/or cotinine, dispersions, and use thereof
US7592458B2 (en) *	2006-07-21	2009-09-22	Wright George E	Dermal anesthetic compounds and pharmaceutical compositions for inducing local anesthesia and mitigating neuropathic pain
RU2463038C2 (ru)	2006-10-17	2012-10-10	Нуво Рисерч Инк.	Диклофенаковый гель
WO2008139264A2 (en) *	2006-11-27	2008-11-20	National Research Council Of Canada	Soft gel formulations
WO2008070538A2 (en)	2006-12-01	2008-06-12	Anterios, Inc.	Micellar nanoparticles comprising botulinum toxin
SG10201607909WA (en)	2006-12-01	2016-11-29	Anterios Inc	Peptide nanoparticles and uses therefor
US9918934B2 (en) †	2006-12-12	2018-03-20	Edgar Joel Acosta-Zara	Linker-based lecithin microemulsion delivery vehicles
WO2008151022A2 (en)	2007-05-31	2008-12-11	Anterios, Inc.	Nucleic acid nanoparticles and uses therefor
EP2055298A1 (de) *	2007-10-30	2009-05-06	Novartis AG	Topische Zusammensetzung
JP5340954B2 (ja) *	2007-11-16	2013-11-13	テクノガード株式会社	薬物含有脂肪乳剤およびその製造方法
US7943187B2 (en) *	2008-05-23	2011-05-17	Bakr Rabie	Paeoniflorin preparations and uses thereof for fat reduction
FR2934954B1 (fr)	2008-08-14	2011-07-22	Commissariat Energie Atomique	Emulsion fluorescente de vert d'indocyanine
FR2934953B1 (fr)	2008-08-14	2011-01-21	Commissariat Energie Atomique	Nanoemulsions de nanocristaux
FR2934955B1 (fr)	2008-08-14	2011-07-08	Commissariat Energie Atomique	Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
CA2751884C (en)	2009-01-14	2018-09-25	Corium International, Inc.	Transdermal administration of tamsulosin
US8618164B2 (en)	2009-03-31	2013-12-31	Nuvo Research Inc.	Treatment of pain with topical diclofenac compounds
SG10201401297QA (en)	2009-04-08	2014-08-28	Cadila Healthcare Ltd	Stable pharmaceutical compositions of diclofenac
WO2012053010A2 (en)	2010-10-21	2012-04-26	Cadila Healthcare Limited	Method for treatment of acne using pharmaceutical compositions of clindamycin
WO2012053009A2 (en)	2010-10-21	2012-04-26	Cadila Healthcare Limited	Pharmaceutical compositions comprising skin whitening agents
MX2013004296A (es)	2010-10-21	2013-09-26	Cadila Healthcare Ltd	Composiciones farmaceuticas topicas que contienen gotas de tamaño nanometrico para el tratamiento de soriasis.
WO2012053014A2 (en)	2010-10-21	2012-04-26	Cadila Healthcare Limited	Method for treatment of acne using pharmaceutical compositions of clindamycin and adapalene
MX2013004248A (es)	2010-10-21	2013-07-22	Cadila Healthcare Ltd	Composiciones farmaceuticas topicas que comprenden etodolaco.
WO2012053012A2 (en)	2010-10-21	2012-04-26	Cadila Healthcare Limited	Topical pharmaceutical compositions comprising tfflocolchicoside
US9789123B2 (en)	2010-10-21	2017-10-17	Cadila Healthcare Limited	Topical pharmaceutical compositions containing nanodroplets for the treatment of psoriasis
US10028972B2 (en)	2010-10-21	2018-07-24	Cadila Healthcare Limited	Pharmaceutical compositions of anti-acne agents
WO2012127496A1 (en) *	2011-03-01	2012-09-27	Cadila Healthcare Limited	Stable pharmaceutical compositions of lornoxicam or salts thereof
US9713590B2 (en) *	2011-07-28	2017-07-25	Cadila Healthcare Limited	Method for treatment of pain and inflammation
US8936814B2 (en) *	2012-11-30	2015-01-20	Zuri A. Murrell	Skin cream
WO2014106048A2 (en)	2012-12-31	2014-07-03	Jrx Biotechnology, Inc.	Liquid topical pharmaceutical nano-emulsion formulations
DE102014102400A1 (de) *	2014-02-25	2015-08-27	Reinhard Caliebe	Topische kosmetische oder pharmazeutische Zusammensetzung
CN106102778A (zh) *	2014-03-27	2016-11-09	宝丽制药股份有限公司	乳化剂型的组合物的制造方法
CA3050535C (en) *	2014-12-15	2021-11-09	Richard Clark Kaufman	Methods of treating inflammatory disorders and global inflammation with compositions comprising phospholipid nanoparticle encapsulations of anti-inflammatory nutraceuticals
US10596117B1 (en) *	2014-12-31	2020-03-24	Eric Morrison	Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en)	2014-12-31	2021-05-18	Eric Morrison	Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
KR20180053318A (ko)	2015-09-17	2018-05-21	제이알엑스 바이오테크놀로지, 인코포레이티드	피부 수화 또는 보습을 향상시키기 위한 접근법
JP6721960B2 (ja) *	2015-09-28	2020-07-15	株式会社ポーラファルマ	皮膚外用剤及びその製造方法並びに有効成分の放出性の向上方法及び放出性の評価方法
US10172838B1 (en)	2016-03-15	2019-01-08	Florida A&M University	Self-emulsifying formulation of CARP-1 functional mimetics
AU2017360346B2 (en)	2016-11-21	2023-11-23	Eirion Therapeutics, Inc.	Transdermal delivery of large agents
AU2021272476A1 (en) *	2020-05-13	2022-12-15	Follicle Pharma Ltd	Compositions for delivery of bioactive agents into hair follicles
FR3120787B1 (fr) *	2021-03-19	2024-04-26	Algotherapeutix	Composition pharmaceutique topique comprenant de l’amitriptyline et une phase aqueuse alcaline
RU2765470C1 (ru) *	2021-03-23	2022-01-31	Иршад Султанович Шарафутдинов	Антибактериальное средство в форме геля на основе гентамицина и производного 2(5н)-фуранона

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7713618L (sv) *	1977-12-01	1979-06-02	Astra Laekemedel Ab	Lokalanestetisk blandning
EP0014509A3 (de) *	1979-02-08	1981-02-11	THE PROCTER & GAMBLE COMPANY	Zusammensetzungen zum Konditionieren der Haut
JPS57171912A (en) *	1981-04-14	1982-10-22	Sumitomo Chem Co Ltd	Cream
FR2520253A1 (fr) *	1982-01-28	1983-07-29	Oreal	Nouveau systeme emulsionnant a base d'un condensat de proteines, d'un sterol polyoxyethylene et de phosphatide et son utilisation en cosmetique
US4613330A (en) *	1982-11-26	1986-09-23	Michelson Paul E	Delivery system for desired agents
US4963367A (en) *	1984-04-27	1990-10-16	Medaphore, Inc.	Drug delivery compositions and methods
JPH0647533B2 (ja) *	1984-08-10	1994-06-22	裕水島	４−ビフエニリル酢酸系化合物含有脂肪乳剤
IL88076A (en) *	1987-10-28	1993-01-14	Nippon Shinyaku Co Ltd	Fat emulsions as drug carriers
DE68917544T2 (de) *	1988-06-20	1994-12-15	Shiseido Co Ltd	Durchsichtiges Präparat.
US5039527A (en) *	1989-02-24	1991-08-13	Medicontrol Corporation	Hexamethylmelamine containing parenteral emulsions
AU614465B2 (en) *	1989-04-05	1991-08-29	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Medicinal emulsions
JPH0344322A (ja) *	1989-07-13	1991-02-26	Shiseido Co Ltd	マイクロエマルション製剤及びその製造法
FR2655542B1 (fr) *	1989-12-13	1994-02-11	Oreal	Composition cosmetique pour application topique contenant des huiles essentielles.
CA2052950A1 (en) *	1990-10-10	1992-04-11	David P. Evitts	Aqueous ophthalmic microemulsions of tepoxalin
AU658608B2 (en) *	1991-03-25	1995-04-27	Astellas Pharma Europe B.V.	Topical preparation containing a suspension of solid lipid particles
CA2130357A1 (en) *	1992-02-18	1993-08-19	Doron Friedman	Dry compositions for preparing submicron emulsions
IL101241A (en) *	1992-03-16	1997-11-20	Yissum Res Dev Co	Pharmaceutical or cosmetic composition comprising stabilized oil-in-water type emulsion as carrier

1992
- 1992-03-26 IL IL10138792A patent/IL101387A/en active IP Right Grant
1993
- 1993-03-23 US US08/036,116 patent/US6004566A/en not_active Expired - Fee Related
- 1993-03-25 JP JP51683693A patent/JP4173533B2/ja not_active Expired - Fee Related
- 1993-03-25 CA CA002132736A patent/CA2132736C/en not_active Expired - Fee Related
- 1993-03-25 AT AT93908578T patent/ATE210425T1/de not_active IP Right Cessation
- 1993-03-25 ES ES93908578T patent/ES2169042T3/es not_active Expired - Lifetime
- 1993-03-25 WO PCT/US1993/002800 patent/WO1993018752A1/en not_active Ceased
- 1993-03-25 AU AU39352/93A patent/AU684460B2/en not_active Ceased
- 1993-03-25 EP EP93908578A patent/EP0671903B1/de not_active Expired - Lifetime
- 1993-03-25 DE DE69331335T patent/DE69331335T2/de not_active Expired - Fee Related
- 1993-03-25 DK DK93908578T patent/DK0671903T3/da active
- 1993-03-25 CA CA002590810A patent/CA2590810A1/en not_active Abandoned
- 1993-03-26 ZA ZA932170A patent/ZA932170B/xx unknown
1999
- 1999-05-12 IL IL12992199A patent/IL129921A/en active IP Right Grant

Also Published As

Publication number	Publication date
IL129921A0 (en)	2000-02-29
EP0671903A1 (de)	1995-09-20
IL129921A (en)	2004-09-27
JP4173533B2 (ja)	2008-10-29
DE69331335D1 (de)	2002-01-24
DE69331335T2 (de)	2002-08-08
EP0671903B1 (de)	2001-12-12
DK0671903T3 (da)	2002-04-15
CA2590810A1 (en)	1993-09-30
JPH07505368A (ja)	1995-06-15
ES2169042T3 (es)	2002-07-01
ZA932170B (en)	1993-10-28
CA2132736C (en)	2007-09-11
US6004566A (en)	1999-12-21
ATE210425T1 (de)	2001-12-15
CA2132736A1 (en)	1993-09-30
AU3935293A (en)	1993-10-21
AU684460B2 (en)	1997-12-18
EP0671903A4 (de)	1996-01-17
WO1993018752A1 (en)	1993-09-30
IL101387A0 (en)	1992-11-15

Legal Events

Date	Code	Title	Description
2000-06-01	FF	Patent granted
2000-08-31	KB	Patent renewed

Publication	Publication Date	Title
IL101387A (en)	1999-11-30	Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
US6113921A (en)	2000-09-05	Topical and transdermal delivery system utilizing submicron oil spheres
Schwarz et al.	1995	Enhanced transdermal delivery of diazepam by submicron emulsion (SME) creams
KR100212926B1 (ko)	1999-08-02	고체 지질 입자의 현탁액을 함유한 국소제제
US5314685A (en)	1994-05-24	Anhydrous formulations for administering lipophilic agents
JP2676281B2 (ja)	1997-11-12	皮膚への局所適用による表皮上層の化粧的および（または）薬学的処置のための組成物およびその製造方法
CN1130195C (zh)	2003-12-10	基于乙氧化脂肪醚或乙氧化脂肪酯的毫微乳及其用途
EP0782855B1 (de)	2001-09-12	Nimesulid zur aüsserlichen anwendung
WO2004064769A2 (en)	2004-08-05	Methods for making and using topical delivery agents
KR20060061879A (ko)	2006-06-08	나노사이즈의 리포좀과 수중유상 에멀젼을 포함하는화장료 조성물 및 그 제조방법
JP4444149B2 (ja)	2010-03-31	超微細エマルジョンで構成される皮膚外用剤
JP3565975B2 (ja)	2004-09-15	皮膚外用剤
US5677341A (en)	1997-10-14	Emulsion suitable for administering a sphingolipid
WO2021229578A1 (en)	2021-11-18	Compositions for delivery of bioactive agents into hair follicles
US20120201857A1 (en)	2012-08-09	Transdermal delivery system for therapeutics
Usmania et al.	2017	Minoxidil emulgel for androgenic alopecia: a literature review including patents
US11197831B2 (en)	2021-12-14	Compositions comprising at least one dispersed active principle and lipid microcapsules
JPH04300831A (ja)	1992-10-23	９−メチル−３−（１Ｈ−テトラゾール−５−イル）−４Ｈ−ピリド〔１，２−ａ〕ピリミジン−４−オン又はその塩のクリーム剤
KR20140067222A (ko)	2014-06-05	레티노이드 유도체를 안정화시킨 수중유형 유화 화장료 조성물